Stockscreener 앱 받기
1.28
0.00%
0.00
시간 외 거래:
1.30
0.02
+1.56%
전일 마감가:
$1.28
열려 있는:
$1.31
하루 거래량:
713.77K
Relative Volume:
1.29
시가총액:
$161.60M
수익:
-
순이익/손실:
$-26.91M
주가수익비율:
-5.12
EPS:
-0.25
순현금흐름:
$-19.57M
1주 성능:
-20.99%
1개월 성능:
-11.72%
6개월 성능:
-18.47%
1년 성능:
+88.24%
1일 변동 폭
$1.265
$1.33
1주일 범위
$1.265
$1.62
52주 변동 폭
$0.6702
$2.31
Atossa Therapeutics Inc Stock (ATOS) Company Profile
명칭
Atossa Therapeutics Inc
전화
206.588.0256
주소
10202 5TH AVENUE NE, SEATTLE, WA
ATOS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ATOS | 1.28 | 161.60M | 0 | -26.91M | -19.57M | -0.25 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2018-01-26 | 개시 | Maxim Group | Buy |
Atossa Therapeutics Inc 주식(ATOS)의 최신 뉴스
FY2024 EPS Estimates for ATOS Boosted by Cantor Fitzgerald - MarketBeat
What is HC Wainwright's Estimate for ATOS FY2026 Earnings? - MarketBeat
Atossa Genetics stock target lifted, retains buy on positive study results - Investing.com UK
Atossa Therapeutics: Q3 2024 Financial Results and Updates - TipRanks
Atossa Therapeutics Inc (ATOS) Quarterly 10-Q Report - Quartzy
Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth - Simply Wall St
Atossa Therapeutics (NASDAQ:ATOS) Downgraded to “Sell” Rating by StockNews.com - Defense World
Atossa Therapeutics (NASDAQ:ATOS) Downgraded to "Sell" Rating by StockNews.com - MarketBeat
Atossa Therapeutics: Important News, But The Company Still Has A Long Way To Go - Seeking Alpha
Atossa Therapeutics (NASDAQ:ATOS) Stock Crosses Above 200 Day Moving AverageShould You Sell? - MarketBeat
Atossa Genetics shares hold Buy rating on positive trial results By Investing.com - Investing.com Canada
Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development - The Manila Times
Atossa Therapeutics Strengthens Leadership Team with Key Clinical Development Executive | ATOS Stock News - StockTitan
Vanguard Group Inc's Strategic Acquisition of Atossa Therapeutics Inc Shares - GuruFocus.com
Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results: - The Manila Times
Atossa Therapeutics (NASDAQ:ATOS) Receives “Buy” Rating from HC Wainwright - Defense World
Atossa Therapeutics' (ATOS) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
ATOSAtossa Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer - ForexTV.com
Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen's Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer - The Manila Times
Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s - The Bakersfield Californian
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year? - Yahoo Finance
Atossa Therapeutics (NASDAQ:ATOS) Upgraded to "Hold" at StockNews.com - MarketBeat
Atossa Therapeutics (NASDAQ:ATOS) Shares Cross Above 200 Day Moving AverageHere's Why - MarketBeat
Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer - The Manila Times
Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit - The Manila Times
Atossa Therapeutics To Present At The 2024 Maxim Healthcare Virtual Summit - Barchart
Atossa Therapeutics (NASDAQ:ATOS) Share Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Atossa Therapeutics Inc [ATOS] Investment Guide: What You Need to Know - Knox Daily
Is Atossa Therapeutics Inc (ATOS) worth investing in despite its overvalued state? - US Post News
Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum - The Manila Times
Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for - The Bakersfield Californian
Rhumbline Advisers Makes New $161,000 Investment in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Was Atossa Therapeutics Inc (ATOS)’s session last reading good? - US Post News
Bank of New York Mellon Corp Buys 399,041 Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) - MarketBeat
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by Bank of New York Mellon Corp - Defense World
What Has Been Going On With Atossa Therapeutics Inc (NASDAQ: ATOS) - Stocks Register
Atossa Therapeutics Inc (ATOS) can make a big difference with a little luck - SETE News
Atossa Therapeutics (NASDAQ:ATOS) Shares Pass Above Two Hundred Day Moving Average of $1.41 - MarketBeat
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
What is the investor’s view on Atossa Therapeutics Inc (ATOS)? - US Post News
Potential Price Increase for Atossa Therapeutics Inc (ATOS) After Recent Insider Activity - Knox Daily
Ratios Reveal: Breaking Down Atossa Therapeutics Inc (ATOS)’s Financial Health - The Dwinnex
Atossa Therapeutics Inc: Weathering Stock Market Storms with 182.35M Market Cap - The InvestChronicle
Taking on analysts’ expectations and winning: Atossa Therapeutics Inc (ATOS) - SETE News
Examining Atossa Therapeutics Inc (ATOS) stock is warranted - US Post News
Atossa Therapeutics (NASDAQ:ATOS) Price Target Increased to $6.50 by Analysts at Ascendiant Capital Markets - Defense World
Analyzing Atossa Therapeutics Inc (ATOS) After Recent Trading Activity - Knox Daily
Atossa Therapeutics (NASDAQ:ATOS) Price Target Raised to $6.50 - MarketBeat
Atossa Therapeutics Inc’s Shares Reel: 21.67% Quarterly Revenue Decline Amid 183.61M Market Cap - The InvestChronicle
Atossa Therapeutics Inc (ATOS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):